Advertisement

Follow us on Twitter @CR_AACR!

From the Current Issue

  • Chromosomal Instability and mTORC1 Activation through PTEN Loss Contribute to Proteotoxic Stress in Ovarian Carcinoma
    Tumor Biology and Immunology
    Chromosomal Instability and mTORC1 Activation through PTEN Loss Contribute to Proteotoxic Stress in Ovarian Carcinoma
    M. Herman Chui, Sasha A. Doodnauth, Natalie Erdmann, Rodger E. Tiedemann, Fabrice Sircoulomb, Ronny Drapkin, Patricia Shaw and Robert Rottapel
    Cancer Res November 1 2019 79 (21) 5536-5549; DOI:10.1158/0008-5472.CAN-18-3029

    Chromosome instability and protein synthesis are important factors that determine the efficacy of proteotoxic stress-inducing agents, such as proteasome inhibitors, in the treatment of ovarian cancer.

  • Priority Report
    HDAC6 Inhibition Synergizes with Anti-PD-L1 Therapy in ARID1A-Inactivated Ovarian Cancer
    Takeshi Fukumoto, Nail Fatkhutdinov, Joseph A. Zundell, Evgenii N. Tcyganov, Timothy Nacarelli, Sergey Karakashev, Shuai Wu, Qin Liu, Dmitry I. Gabrilovich and Rugang Zhang
    Cancer Res November 1 2019 79 (21) 5482-5489; DOI:10.1158/0008-5472.CAN-19-1302

    These findings offer a mechanistic rationale for combining epigenetic modulators and existing immunotherapeutic interventions against a disease that has been so far resistant to checkpoint blockade as a monotherapy.

  • Translational Science | AuthorChoice
    Cellular and Genetic Determinants of the Sensitivity of Cancer to α-Particle Irradiation
    Brian D. Yard, Priyanka Gopal, Kristina Bannik, Gerhard Siemeister, Urs B. Hagemann and Mohamed E. Abazeed
    Cancer Res November 1 2019 79 (21) 5640-5651; DOI:10.1158/0008-5472.CAN-19-0859

    These findings address limitations in the preclinical guidance and prediction of radionuclide tumor sensitivity by identifying intrinsic cellular and genetic determinants of cancer cell survival following exposure to α-particle irradiation.

See the Table of Contents

Recent Reviews

OnlineFirst Articles

Load more
Advertisement

Back to top